[Click eStock] "Samil Pharmaceutical, Growth Expected with Exclusive Sales of Osteoarthritis Treatment"

Research Alume forecasted on the 21st that Samil Pharmaceutical could achieve structural growth through the exclusive domestic sales of the osteoarthritis treatment 'Lorecivivint.'

Researcher Seunghwan Lee from Research Alume explained, "Samil Pharmaceutical has secured the exclusive domestic distribution rights for Lorecivivint from the U.S. biotech company Biosplice." He added, "Osteoarthritis is one of the common diseases," and "According to the National Health Insurance Service, about 37.8% of osteoarthritis patients aged 50 and above in Korea show grade 2 or higher osteoarthritis."

He stated, "Generally, after prescribing acetaminophen, NSAIDs are given, and if the pain does not subside, opioid-based analgesics such as tramadol are prescribed," emphasizing, "Intra-articular steroid injections can be administered for localized inflammation control, but long-term use is not recommended."

Researcher Lee said, "Osteoarthritis treatments are useful medicines that can treat the condition without surgery," and analyzed, "Assuming annual sales of about 2.5 million KRW per person, even conservatively considering a penetration rate of about 5% and a profit margin of about 10%, it is expected to secure at least 30 billion KRW in annual profits."

원본보기 아이콘

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.